Blood glucose Archives - Revista Brasileira de Ginecologia e Obstetrícia
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2013;35(11):511-515
DOI 10.1590/S0100-72032013001100006
PURPOSE: To evaluate the incidence of maternal and fetal repercussions and glycemic control in women with Gestational Diabetes Mellitus (GDM) using a fasting glucose of 85 mg/dL in the first trimester as a cut-off point and to correlate it with risk factors. METHODS: The medical records of pregnant women followed in the outpatient antenatal high-risk service (PNAR) of HRAN from January 2011 to March 2012 were reviewed and those women diagnosed with GDM were selected for contact and for prenatal card verification. We collected data of age, parity, fasting glucose during the first quarter, the value of the Oral Glucose Tolerance Test (OGTT), Body Mass Index (BMI), mode of delivery, form of control, effects and fetal risk factors for GDM. Statistical analysis was performed using the PSPP 0.6.2 software and consisted of descriptive analysis of frequencies, χ2 test for categorical variables, Student's t-test for independent samples, and Pearson test for correlations, with the level of significance set at 5%. RESULTS: From 408 pregnant women enrolled, 105 were diagnosed with GDM and 71 had complete records or answered to the contact in order to provide the missing information. The GDM-fasting <85 (fasting glucose <85 mg/dL at the first prenatal visit, in the first trimester) group consisted of 29 (40.8%) women and the GDM-fasting >85 (fasting glucose >85 mg/dL at the first prenatal visit, in the first trimester) consisted of 42 (59.1%) women. It was observed that few patients (five in the GDM-fasting <85 group and three in the GDM-fasting >85 group) had no risk factors for GDM. There was a major need for control with insulin in patients of the GDM-fasting >85 group. There was no significant difference related to fetal impact or mode of delivery between the groups. CONCLUSIONS: The first trimester fasting glycemia, with a cut-off value of 85 mg/dL alone or associated with risk factors, does not seem to be a good single predictor of the maternal-fetal effects of GDM.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2013;35(11):511-515
DOI 10.1590/S0100-72032013001100006
PURPOSE: To evaluate the incidence of maternal and fetal repercussions and glycemic control in women with Gestational Diabetes Mellitus (GDM) using a fasting glucose of 85 mg/dL in the first trimester as a cut-off point and to correlate it with risk factors. METHODS: The medical records of pregnant women followed in the outpatient antenatal high-risk service (PNAR) of HRAN from January 2011 to March 2012 were reviewed and those women diagnosed with GDM were selected for contact and for prenatal card verification. We collected data of age, parity, fasting glucose during the first quarter, the value of the Oral Glucose Tolerance Test (OGTT), Body Mass Index (BMI), mode of delivery, form of control, effects and fetal risk factors for GDM. Statistical analysis was performed using the PSPP 0.6.2 software and consisted of descriptive analysis of frequencies, χ2 test for categorical variables, Student's t-test for independent samples, and Pearson test for correlations, with the level of significance set at 5%. RESULTS: From 408 pregnant women enrolled, 105 were diagnosed with GDM and 71 had complete records or answered to the contact in order to provide the missing information. The GDM-fasting <85 (fasting glucose <85 mg/dL at the first prenatal visit, in the first trimester) group consisted of 29 (40.8%) women and the GDM-fasting >85 (fasting glucose >85 mg/dL at the first prenatal visit, in the first trimester) consisted of 42 (59.1%) women. It was observed that few patients (five in the GDM-fasting <85 group and three in the GDM-fasting >85 group) had no risk factors for GDM. There was a major need for control with insulin in patients of the GDM-fasting >85 group. There was no significant difference related to fetal impact or mode of delivery between the groups. CONCLUSIONS: The first trimester fasting glycemia, with a cut-off value of 85 mg/dL alone or associated with risk factors, does not seem to be a good single predictor of the maternal-fetal effects of GDM.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2010;32(5):222-228
DOI 10.1590/S0100-72032010000500004
PURPOSE: to compare two screening tests for diabetes and their results to pregnancy outcomes. METHODS: in total, 279 pregnant women were submitted to two screening tests for gestational diabetes - fasting glycemia plus risk factors (FG + RF) and to the simplified glucose tolerance test (GTT50g). Screening by FG + RF consisted of the determination of fasting glycemia and anamnesis for the identification of risk factors on the occasion of the first prenatal visit. The GTT50g was performed between the 24th and the 28th week of pregnancy and consisted of the determination of plasma glycemia under fasting conditions and one hour after an oral overload with 50 g glucose. Positive and negative results were compared to pregnancy outcome. The dependent variables were: type of delivery, gestational age, weight and ponderal index at birth, Apgar indexes <7 in the 1st and 5th minutes, need for admission to the Intensive Care Unit (ICU), duration of hospitalization, and neonatal death. Data were analyzed statistically through the Students t-test, and the level of significance was set at 5%. RESULTS: only two of the perinatal variables studied were distinguished by the tests. An abnormal GTT50g was associated with a greater proportion of cesarean deliveries (58.7 versus 34.3%) and a positive FG + RF association was related to a higher rate of premature births (15.4 versus 5.4%). The other dependent variables did not differ among patients with positive and negative results of the two screening tests. CONCLUSIONS: despite the relation between prematurity and a positive FG + RF association, the increase of caesarean sections and the abnormal GTT50g, it would be a critical failure to accept these associations as definitive. Among others explanations, multiple intercurrent factors and the characteristics of the screening tests themselves should be considered.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2010;32(5):222-228
DOI 10.1590/S0100-72032010000500004
PURPOSE: to compare two screening tests for diabetes and their results to pregnancy outcomes. METHODS: in total, 279 pregnant women were submitted to two screening tests for gestational diabetes - fasting glycemia plus risk factors (FG + RF) and to the simplified glucose tolerance test (GTT50g). Screening by FG + RF consisted of the determination of fasting glycemia and anamnesis for the identification of risk factors on the occasion of the first prenatal visit. The GTT50g was performed between the 24th and the 28th week of pregnancy and consisted of the determination of plasma glycemia under fasting conditions and one hour after an oral overload with 50 g glucose. Positive and negative results were compared to pregnancy outcome. The dependent variables were: type of delivery, gestational age, weight and ponderal index at birth, Apgar indexes <7 in the 1st and 5th minutes, need for admission to the Intensive Care Unit (ICU), duration of hospitalization, and neonatal death. Data were analyzed statistically through the Students t-test, and the level of significance was set at 5%. RESULTS: only two of the perinatal variables studied were distinguished by the tests. An abnormal GTT50g was associated with a greater proportion of cesarean deliveries (58.7 versus 34.3%) and a positive FG + RF association was related to a higher rate of premature births (15.4 versus 5.4%). The other dependent variables did not differ among patients with positive and negative results of the two screening tests. CONCLUSIONS: despite the relation between prematurity and a positive FG + RF association, the increase of caesarean sections and the abnormal GTT50g, it would be a critical failure to accept these associations as definitive. Among others explanations, multiple intercurrent factors and the characteristics of the screening tests themselves should be considered.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2007;29(5):253-259
DOI 10.1590/S0100-72032007000500006
PURPOSE: to evaluate the insulin therapy protocol and its maternal and perinatal outcome in patients with clinical or gestational diabetes in a high risk reference service. METHODS: descriptive and prospective study including 103 pregnant women with gestational or clinical diabetes treated with insulin and attended by the reference service from October 2003 to December 2005. Gemellarity, miscarriages, unfinished prenatal care and deliveries not attended by the service were excluded. The gestational age at the beginning of the treatment, dosage, doses/day, increment of insulin (UI/kg), glycemic index (GI) and perinatal outcomes were compared. ANOVA, Fisher’s exact test and Goodman’s test considering p<0.05 were used. RESULTS: multiparity (92 versus 67.9%), pre-gestational body mass index (BMI) >25 kg/m² (88 versus 58.5%), weight gain (WG) <8 kg (36 versus 17%) and a high increment of insulin characterized the gestational diabetes. For the patients with clinical diabetes, despite the highest GI (120 mg/dL (39.2 versus 24%)) at the end of the gestational period, insulin therapy started earlier (47.2 versus 4%), lasted longer (56.6 versus 6%) and higher doses of insulin (92 versus 43 UI/day) were administered up to three times a day (54.7 versus 16%). Macrosomia was higher among newborns from the cohort of patients with gestational diabetes (16 versus 3.8%), being the only significant neonatal outcome. There were no neonatal deaths, except for one fetal death in the cohort of patients with clinical diabetes. There were no differences in the other neonatal complications in both cohorts, and most of the newborns were discharged from hospital up to seven days after delivery (46% versus 55.8%). CONCLUSIONS: the analysis of these two cohorts has shown differences in the insulin therapy protocol in quantity (UI/day), dosage (UI/kg weight) and number of doses/day, higher for the clinical diabetes cohort, and in the increment of insulin, higher for the gestational diabetes cohort. Indirectly, the quality of maternal glycemic control and the satisfactory perinatal outcome have proven that the treatment protocol was adequate and did not depend on the type of diabetes.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2007;29(5):253-259
DOI 10.1590/S0100-72032007000500006
PURPOSE: to evaluate the insulin therapy protocol and its maternal and perinatal outcome in patients with clinical or gestational diabetes in a high risk reference service. METHODS: descriptive and prospective study including 103 pregnant women with gestational or clinical diabetes treated with insulin and attended by the reference service from October 2003 to December 2005. Gemellarity, miscarriages, unfinished prenatal care and deliveries not attended by the service were excluded. The gestational age at the beginning of the treatment, dosage, doses/day, increment of insulin (UI/kg), glycemic index (GI) and perinatal outcomes were compared. ANOVA, Fisher’s exact test and Goodman’s test considering p<0.05 were used. RESULTS: multiparity (92 versus 67.9%), pre-gestational body mass index (BMI) >25 kg/m² (88 versus 58.5%), weight gain (WG) <8 kg (36 versus 17%) and a high increment of insulin characterized the gestational diabetes. For the patients with clinical diabetes, despite the highest GI (120 mg/dL (39.2 versus 24%)) at the end of the gestational period, insulin therapy started earlier (47.2 versus 4%), lasted longer (56.6 versus 6%) and higher doses of insulin (92 versus 43 UI/day) were administered up to three times a day (54.7 versus 16%). Macrosomia was higher among newborns from the cohort of patients with gestational diabetes (16 versus 3.8%), being the only significant neonatal outcome. There were no neonatal deaths, except for one fetal death in the cohort of patients with clinical diabetes. There were no differences in the other neonatal complications in both cohorts, and most of the newborns were discharged from hospital up to seven days after delivery (46% versus 55.8%). CONCLUSIONS: the analysis of these two cohorts has shown differences in the insulin therapy protocol in quantity (UI/day), dosage (UI/kg weight) and number of doses/day, higher for the clinical diabetes cohort, and in the increment of insulin, higher for the gestational diabetes cohort. Indirectly, the quality of maternal glycemic control and the satisfactory perinatal outcome have proven that the treatment protocol was adequate and did not depend on the type of diabetes.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2006;28(12):693-699
DOI 10.1590/S0100-72032006001200002
PURPOSE: to analyze the effect of glucose in the materno-fetal hemodynamics through dopplervelocimetric assessment of the materno-fetal and fetoplacentary circulation. METHODS: the study was carried out by a single observer on 31 clinically healthy pregnant women from the 28th to the 36th gestational week. Parameters were assessed immediately before or 60 minutes after the ingestion of 50 g of glucose. The including criteria comprised normal clinical and laboratorial evaluation, the presence of only one fetus, gestational age between 28 and 36 weeks confirmed by ultrasonography and/or the date of the last menstruation, fasting glycemia less or equal to 110 mg/dL and less than 140 mg/dL after 50 g of glucose overload. The excluding criteria consisted of the presence of fetal malformation or development alterations, labor, diabetes as a family predisposition, pathologies due to or underlying gestation and use of tobacco, alcohol and/or other substances. The mother´s common carotid artery and uterine arteries, the umbilical artery and the fetal medial cerebral artery and abdominal aorta were evaluated. In each blood vessel, the following parameters were analyzed: resistance index, pulsatility index, maximum systolic speed, final diastolic speed and acceleration time. The fetal heart rate was evaluated by M Mode ultrasonography. For the statistical analysis, the Student's t test was used when the variable presented normal distribution in Kolmogorov-Smirnov's test. When normality was rejected, the Wilcoxon's non-parametric test was used, with the significance level always established at p<0.05. RESULTS: the maternal glycemia increased after the ingestion of 50 g of glucose (before: 68.0±10.1 mg/dL and after: 104.6±28.2 mg/dL; p<0.001), and fetal heart rate decreased after the glucose ingestion (before: 137.9±6.1 bpm and after: 134.5±6.9 bpm; p<0.001). The umbilical artery presented an increase in the pulsatility index (before: 0.8±0.1 and after: 0.9±0.2; p=0.03). Significant velocimetric alterations were not found in the other vessels or in the other indexes investigated. CONCLUSIONS: in spite of the variation in the levels of maternal glycemia and in the fetal heart rate following glucose ingestion, no significant flow alteration occurred in the following vessels: umbilical artery, fetal medial cerebral artery and aorta; nor in the carotid and uterine maternal arteries. We conclude that the glucose concentration used was released without hemodynamic interference in the materno-fetal compartment.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2006;28(12):693-699
DOI 10.1590/S0100-72032006001200002
PURPOSE: to analyze the effect of glucose in the materno-fetal hemodynamics through dopplervelocimetric assessment of the materno-fetal and fetoplacentary circulation. METHODS: the study was carried out by a single observer on 31 clinically healthy pregnant women from the 28th to the 36th gestational week. Parameters were assessed immediately before or 60 minutes after the ingestion of 50 g of glucose. The including criteria comprised normal clinical and laboratorial evaluation, the presence of only one fetus, gestational age between 28 and 36 weeks confirmed by ultrasonography and/or the date of the last menstruation, fasting glycemia less or equal to 110 mg/dL and less than 140 mg/dL after 50 g of glucose overload. The excluding criteria consisted of the presence of fetal malformation or development alterations, labor, diabetes as a family predisposition, pathologies due to or underlying gestation and use of tobacco, alcohol and/or other substances. The mother´s common carotid artery and uterine arteries, the umbilical artery and the fetal medial cerebral artery and abdominal aorta were evaluated. In each blood vessel, the following parameters were analyzed: resistance index, pulsatility index, maximum systolic speed, final diastolic speed and acceleration time. The fetal heart rate was evaluated by M Mode ultrasonography. For the statistical analysis, the Student's t test was used when the variable presented normal distribution in Kolmogorov-Smirnov's test. When normality was rejected, the Wilcoxon's non-parametric test was used, with the significance level always established at p<0.05. RESULTS: the maternal glycemia increased after the ingestion of 50 g of glucose (before: 68.0±10.1 mg/dL and after: 104.6±28.2 mg/dL; p<0.001), and fetal heart rate decreased after the glucose ingestion (before: 137.9±6.1 bpm and after: 134.5±6.9 bpm; p<0.001). The umbilical artery presented an increase in the pulsatility index (before: 0.8±0.1 and after: 0.9±0.2; p=0.03). Significant velocimetric alterations were not found in the other vessels or in the other indexes investigated. CONCLUSIONS: in spite of the variation in the levels of maternal glycemia and in the fetal heart rate following glucose ingestion, no significant flow alteration occurred in the following vessels: umbilical artery, fetal medial cerebral artery and aorta; nor in the carotid and uterine maternal arteries. We conclude that the glucose concentration used was released without hemodynamic interference in the materno-fetal compartment.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2005;27(8):461-466
DOI 10.1590/S0100-72032005000800005
PURPOSE: to compare the effectiveness of glibenclamide and acarbose with that of insulin for the treatment of gestational diabetes mellitus (GDM), in regard to maternal glucose levels, newborn (NB) weight and neonatal hypoglycemia. METHODS: an open, randomized prospective study was carried out. Fifty-seven patients diagnosed with GDM were included. These patients required dietary control and additional therapy. Pregnant women were randomly alloted to one of three groups with different therapies: a control group making use of insulin therapy, a study group making use of glibenclamide and a study group making use of acarbose. The study took seven months (from October 1st 2003 to May 1st 2004). Assessed outcomes were maternal glucose levels in the prenatal period, the need for replacing therapy to achieve glucose level control, NB weight and neonatal hypoglycemia. Statistical analysis was determined by ANOVA with the level of significance set at 5%. RESULTS: maternal characteristics were similar in all the three groups. Glucose level control was not obtained in three of the patients who used glibenclamide (15%) and in seven (38.8%) of the patients who used acarbose. Regarding fasting and postprandial glucose level rates and average NB weight no difference between the three groups was observed. No statistical difference was found for fasting or postprandial glucose levels and average NB weight in any of the three groups. The rate of large for gestational age fetuses was 5.2, 31.5 and 11.1% for the groups treated with insulin, glibenclamide and acarbose, respectively. Neonatal hypoglycemia was observed in six NB. Four of these were from the glibenclamide group (21.0%). CONCLUSIONS: glibenclamide was more effective for glucose level control than acarbose but neither were more efficient than insulin. NB children whose mothers had been alloted to the glibenclamide group showed a higher rate of macrosomia and neonatal hypoglycemia when compared to those newborns whose mothers were subjected to other therapies.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2005;27(8):461-466
DOI 10.1590/S0100-72032005000800005
PURPOSE: to compare the effectiveness of glibenclamide and acarbose with that of insulin for the treatment of gestational diabetes mellitus (GDM), in regard to maternal glucose levels, newborn (NB) weight and neonatal hypoglycemia. METHODS: an open, randomized prospective study was carried out. Fifty-seven patients diagnosed with GDM were included. These patients required dietary control and additional therapy. Pregnant women were randomly alloted to one of three groups with different therapies: a control group making use of insulin therapy, a study group making use of glibenclamide and a study group making use of acarbose. The study took seven months (from October 1st 2003 to May 1st 2004). Assessed outcomes were maternal glucose levels in the prenatal period, the need for replacing therapy to achieve glucose level control, NB weight and neonatal hypoglycemia. Statistical analysis was determined by ANOVA with the level of significance set at 5%. RESULTS: maternal characteristics were similar in all the three groups. Glucose level control was not obtained in three of the patients who used glibenclamide (15%) and in seven (38.8%) of the patients who used acarbose. Regarding fasting and postprandial glucose level rates and average NB weight no difference between the three groups was observed. No statistical difference was found for fasting or postprandial glucose levels and average NB weight in any of the three groups. The rate of large for gestational age fetuses was 5.2, 31.5 and 11.1% for the groups treated with insulin, glibenclamide and acarbose, respectively. Neonatal hypoglycemia was observed in six NB. Four of these were from the glibenclamide group (21.0%). CONCLUSIONS: glibenclamide was more effective for glucose level control than acarbose but neither were more efficient than insulin. NB children whose mothers had been alloted to the glibenclamide group showed a higher rate of macrosomia and neonatal hypoglycemia when compared to those newborns whose mothers were subjected to other therapies.